1911 | Starting pneumococcal vaccine research development |
1915–1945 | Description of chemical structure of pathogen, virulence factors, antigenicity and serotypes. In 1940 more than 80 serotypes were known. |
1977 | Introduction of pneumococcal polysaccharide vaccine with 14 serotypes (PPV-14) in USA |
1983 | Introduction of pneumococcal polysaccharide vaccine with 23 serotypes (PPV-23) |
2000 | First development of pneumococcal conjugate vaccine with seven serotypes (PCV-7) |
2009 | Introduction of pneumococcal conjugate vaccine with 10 serotypes (PCV-10) received by European Commission authorisation |
2010 | Introduction of 13-valent pneumococcal conjugate vaccine (PCV-13) for children (6 weeks to 71 months) |
December 2011 | First application of PCV-13 in adults ≥50 years |
June 2012 | ACIP recommendation of PCV-13 for adults aged ≥19 years with immunocompromising conditions |
January 2013 | PCV-13 for teenagers (6–17 years) |
July 2013 | EMA recommendation of PCV-13 for all ages |
ACIP, Advisory Committee on Immunization Practices; EMA, European Medicines Agency.